ANAB vs ANL

AnaptysBio, Inc. vs Adlai Nortye Ltd. — Valuation Comparison 2026

ANAB

Biotechnology
AnaptysBio, Inc.
Quality
6.8
out of 10
Value Trap
12
SAFE
Price
$57.02
Last close
Models
11/13
Active
VS

ANL

Biotechnology
Adlai Nortye Ltd.
Quality
1.5
out of 10
Value Trap
12
SAFE
Price
$11.30
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ANAB Fair ValueANAB Upside ANL Fair ValueANL Upside
Bayesian DCF Intrinsic $19.98 -65.0% $2.99 -73.5%
First Chicago Scenario $11.33 -80.1% $24.91 +115.5%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $54.17 -10.3% $7.86 -49.3%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANAB vs ANL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANAB vs ANL — Which Stock Is More Undervalued?

ANAB scores higher with a 6.8/10 quality rating vs ANL's 1.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AnaptysBio, Inc. (ANAB) and Adlai Nortye Ltd. (ANL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANAB currently trades at $57.02 with a QOC of 6.8/10, while ANL trades at $11.30 with a QOC of 1.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).